The DOI matches its Crossref record; 105 of the 105 references it cites were found in a registry or an index.
Mechanisms of Drug Resistance in Cancer Chemotherapy
Abstract
The management of cancer involves procedures, which include surgery, radiotherapy and chemotherapy. Development of chemoresistance is a persistent problem during the treatment of local and disseminated disease. A plethora of cytotoxic drugs that selectively, but not exclusively, target actively proliferating cells include such diverse groups as DNA alkylating agents, antimetabolites, intercalating agents and mitotic inhibitors. Resistance constitutes a lack of response to drug-induced tumour growth inhibition; it may be inherent in a subpopulation of heterogeneous cancer cells or be acquired as a cellular response to drug exposure. Resistance varies. Although regulatory approval may require efficacy in as few as 20% of trial cohorts, a drug may subsequently be used in unselected patients displaying resistance to the treatment. Principal mechanisms may include altered membrane transport involving the P-glycoprotein product of the multidrug resistance (MDR) gene as well as other associated proteins, altered target enzyme (e.g. mutated topoisomerase II), decreased drug activation, increased drug degradation due to altered expression of drug-metabolising enzymes, drug inactivation due to conjugation with increased glutathione, subcellular redistribution, drug interaction, enhanced DNA repair and failure to apoptose as a result of mutated cell cycle proteins such as p53. Attempts to overcome resistance mainly involve the use of combination drug therapy using different classes of drugs with minimally overlapping toxicities to allow maximal dosages and with narrowest cycle intervals, necessary for bone marrow recovery. Adjuvant therapy with P-glycoprotein inhibitors and, in specific instances, the use of growth factor and protein kinase C inhibitors are newer experimental approaches that may also prove effective in abrogating or delaying onset of resistance. Gene knockout using antisense molecules may be another effective way of blocking drug resistance genes. Conversely, drug resistance may also be used to good purpose by transplanting retrovirally transformed CD34 cells expressing the MDR gene to protect the bone marrow during high-dose chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
ABC Transporters: From Microorganisms to Man
Higgins, C. F. (1992) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.08.110192.000435 · Cited by 3,985
A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
Juliano, R. L., & Ling, V. (1976) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(76)90160-7 · Cited by 3,296
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line
Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., & Deeley, R. G. (1992) · Science · doi:10.1126/science.1360704 · Cited by 3,037
Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M. M., Pastan, I., & Willingham, M. C. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.21.7735 · Cited by 2,777
Epidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,690
Hoffmeyer, S., Burk, O., von Richter, O., Arnold, H. P., Brockmöller, J., Johne, A., Cascorbi, I., Gerloff, T., Roots, I., Eichelbaum, M., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3473 · Cited by 2,365
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184
THE BIOCHEMISTRY OF P-GLYCOPROTEIN-MEDIATED MULTIDRUG RESISTANCE
Endicott, J. A., & Ling, V. (1989) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.58.070189.001033 · Cited by 2,071
BIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTER
Ambudkar, S. V., Dey, S., Hrycyna, C. A., Ramachandra, M., Pastan, I., & Gottesman, M. M. (1999) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.39.1.361 · Cited by 2,059
Willett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Sahani, D. V., Kalva, S. P., Kozin, S. V., et al. (2004) · Nature Medicine · doi:10.1038/nm988 · Cited by 1,966
Chen, C.-J., Chin, J. E., Ueda, K., Clark, D. P., Pastan, I., Gottesman, M. M., & Roninson, I. B. (1986) · Cell · doi:10.1016/0092-8674(86)90595-7 · Cited by 1,898
A family of drug transporters: the multidrug resistance-associated proteins
Borst, P., Evers, R., Kool, M., & Wijnholds, J. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.16.1295 · Cited by 1,751
The Human ATP-Binding Cassette (ABC) Transporter Superfamily
Dean, M., Rzhetsky, A., & Allikmets, R. (2001) · Genome Research · doi:10.1101/gr.184901 · Cited by 1,748
Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694
Review of epidermal growth factor receptor biology
Herbst, R. S. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.11.041 · Cited by 1,390
DNA and its associated processes as targets for cancer therapy
Hurley, L. H. (2002) · Nature Reviews Cancer · doi:10.1038/nrc749 · Cited by 1,349
Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., Bohlen, P., & Kerbel, R. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8829 · Cited by 1,168
Ueda, K., Cardarelli, C., Gottesman, M. M., & Pastan, I. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.9.3004 · Cited by 1,063
Genetic contribution to variable human CYP3A-mediated metabolism
Lamba, J. K., Lin, Y. S., Schuetz, E. G., & Thummel, K. E. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00066-2 · Cited by 990
The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
Greiner, B., Eichelbaum, M., Fritz, P., Kreichgauer, H.-P., von Richter, O., Zundler, J., & Kroemer, H. K. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6663 · Cited by 917
Kool, M., de Haas, M., Scheffer, G. L., Scheper, R. J., van Eijk, M. J., Juijn, J. A., Baas, F., & Borst, P. (1997) · PubMed · Cited by 882
Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice
Hanahan, D., Bergers, G., & Bergsland, E. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9872 · Cited by 865
Waxman, D. J. (1999) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1999.1351 · Cited by 753
Litman, T., Druley, T. E., Stein, W. D., & Bates, S. E. (2001) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000912 · Cited by 688
Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair.
Chu, G. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42175-2 · Cited by 651
Rixe, O., Ortuzar, W., Alvarez, M., Parker, R., Reed, E., Paull, K., & Fojo, T. (1996) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)81490-6 · Cited by 615
P-glycoprotein and multidrug resistance
Gottesman, M. M., Pastan, I., & Ambudkar, S. V. (1996) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(96)80091-8 · Cited by 560
Huang, S., & Harari, P. M. (2000) · PubMed · Cited by 555
ABC Transporters and the Blood-Brain Barrier
Begley, D. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043384844 · Cited by 545
Cisplatin and DNA repair in cancer chemotherapy
Zamble, D. B., & Lippard, S. J. (1995) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)89095-7 · Cited by 538
Zaman, G. J., Lankelma, J., van Tellingen, O., Beijnen, J., Dekker, H., Paulusma, C., Oude Elferink, R. P., Baas, F., & Borst, P. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.17.7690 · Cited by 498
Haimeur, A., Conseil, G., Deeley, R., & Cole, S. (2004) · Current Drug Metabolism · doi:10.2174/1389200043489199 · Cited by 485
GENETIC ANALYSIS OF THE MULTIDRUG TRANSPORTER
Gottesman, M. M., Hrycyna, C. A., Schoenlein, P. V., Germann, U. A., & Pastan, I. (1995) · Annual Review of Genetics · doi:10.1146/annurev.ge.29.120195.003135 · Cited by 478
The physiological function of drug-transporting P-glycoproteins
Schinkel, A. H. (1997) · Seminars in Cancer Biology · doi:10.1006/scbi.1997.0068 · Cited by 458
Kerbel, R. S. (1991) · BioEssays · doi:10.1002/bies.950130106 · Cited by 441
Increased drug delivery to the brain by P-glycoprotein inhibition
Sadeque, A. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.109156 · Cited by 426
ICE Family Proteases: Mediators of All Apoptotic Cell Death?
Henkart, P. A. (1996) · Immunity · doi:10.1016/s1074-7613(00)80428-8 · Cited by 420
Drug-target interactions: only the first step in the commitment to a programmed cell death?
Dive, C., & Hickman, J. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.269 · Cited by 398
The ErbB/HER receptor protein-tyrosine kinases and cancer
Roskoski, R. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.04.150 · Cited by 395
Kool, M., van der Linden, M., de Haas, M., Baas, F., & Borst, P. (1999) · PubMed · Cited by 361
Smyth, M. J., Krasovskis, E., Sutton, V. R., & Johnstone, R. W. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.12.7024 · Cited by 356
P-glycoprotein expression and function in circulating blood cells from normal volunteers
Klimecki, W., Futscher, B., Grogan, T., & Dalton, W. (1994) · Blood · doi:10.1182/blood.v83.9.2451.2451 · Cited by 353
Functional involvement of P-glycoprotein in blood-brain barrier.
Tatsuta, T., Naito, M., Oh-hara, T., Sugawara, I., & Tsuruo, T. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)88713-6 · Cited by 347
Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP
Cole, S. P. C., & Deeley, R. G. (1998) · BioEssays · doi:10.1002/(sici)1521-1878(199811)20:11<931::aid-bies8>3.0.co;2-j · Cited by 342
Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells.
Conze, D. B., Weiss, L., Regen, P. S., Bhushan, A., Weaver, D. L., Johnson, P. F., & Rincón, M. (2001) · PubMed · Cited by 334
Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells
Aoudjit, F., & Vuori, K. (2001) · Oncogene · doi:10.1038/sj.onc.1204554 · Cited by 325
Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody.
Mechetner, E. B., & Roninson, I. B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.13.5824 · Cited by 316
Johnstone, R. W., Cretney, E., & Smyth, M. J. (1999) · Blood · doi:10.1182/blood.v93.3.1075 · Cited by 315
Multiple physiological functions for multidrug transporter P-glycoprotein?
JOHNSTONE, R., RUEFLI, A., & SMYTH, M. (2000) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(99)01493-0 · Cited by 309
Shapiro, A. B., Fox, K., Lam, P., & Ling, V. (1999) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1999.00098.x · Cited by 304
Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein
Sikic, B. I. (1997) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800051055 · Cited by 277
The Effect of Rifampin Treatment on Intestinal Expression of Human MRP Transporters
Fromm, M. F., Kauffmann, H.-M., Fritz, P., Burk, O., Kroemer, H. K., Warzok, R. W., Eichelbaum, M., Siegmund, W., & Schrenk, D. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64794-3 · Cited by 277
ATP binding cassette transporters and drug resistance in breast cancer.
Leonessa, F., & Clarke, R. (2003) · Endocrine-related cancer · doi:10.1677/erc.0.0100043 · Cited by 259
Smith, A. J., van Helvoort, A., van Meer, G., Szabó, K., Welker, E., Szakács, G., Váradi, A., Sarkadi, B., & Borst, P. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m909002199 · Cited by 252
EGF, TGF-a, and EGF-R in Human Colorectal Adenocarcinoma
Messa, C., Russo, F., Gabriella Caruso, M., & Di Leo, A. (1998) · Acta Oncologica · doi:10.1080/028418698429595 · Cited by 251
Ciardiello, F., & Tortora, G. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00235-1 · Cited by 245
Porębska, I., Harłozińska, A., & Bojarowski, T. (2000) · Tumor Biology · doi:10.1159/000030116 · Cited by 234
Bandyopadhyay, D., Mandal, M., Adam, L., Mendelsohn, J., & Kumar, R. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.3.1568 · Cited by 229
Folate-Mediated Targeting of Therapeutic and Imaging Agents to Cancers
Reddy, J. A., & Low, P. S. (1998) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v15.i6.20 · Cited by 219
Homolya, L., Váradi, A., & Sarkadi, B. (2003) · BioFactors · doi:10.1002/biof.5520170111 · Cited by 208
Multidrug resistance and the role of P-glycoprotein knockout mice
Schinkel, A. H., Mol, C. A. A. M., Wagenaar, E., van Deemter, L., Smit, J. J. M., & Borst, P. (1995) · European Journal of Cancer · doi:10.1016/0959-8049(95)00130-b · Cited by 199
Fibroblast growth factors: An epigenetic mechanism of broad spectrum resistance to anticancer drugs
Song, S., Wientjes, M. G., Gan, Y., & Au, J. L.-S. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.140210697 · Cited by 195
Protein Kinase C Isozymes as Potential Targets for Anticancer Therapy
Hofmann, J. (2004) · Current Cancer Drug Targets · doi:10.2174/1568009043481579 · Cited by 176
Expression of the multidrug resistance-associated protein (MRP) gene in human cancers.
Nooter, K., Westerman, A. M., Flens, M. J., Zaman, G. J., Scheper, R. J., van Wingerden, K. E., Burger, H., Oostrum, R. G., Boersma, T., & Sonneveld, P. (1995) · PubMed · Cited by 174
Kern, D. H., & Weisenthal, L. M. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.7.582 · Cited by 174
Clinical Relevance of P-Glycoprotein in Drug Therapy
Lin, J. H., & Yamazaki, M. (2003) · Drug Metabolism Reviews · doi:10.1081/dmr-120026871 · Cited by 167
Duesberg, P., Stindl, R., & Hehlmann, R. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.26.14295 · Cited by 165
Penson, R. T., Oliva, E., Skates, S. J., Glyptis, T., Fuller, A. F., Goodman, A., & Seiden, M. V. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2003.11.053 · Cited by 161
Dumontet, C., Fabianowska‐Majewska, K., Mantincic, D., Callet‐Bauchu, E., Tigaud, I., Gandhi, V. V., Lepoivre, M., Peters, G. J., Rolland, M. O., Wyczechowska, D. D., et al. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01509.x · Cited by 151
Chen, Z., Furukawa, T., Sumizawa, T., Ono, K., Ueda, K., Seto, K., & Akiyama, S.-I. (1999) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)23189-8 · Cited by 135
Lecureur, V., Sun, D., Hargrove, P., Schuetz, E. G., Kim, R. B., Lan, L.-B., & Schuetz, J. D. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)26438-5 · Cited by 128
van den Heuvel‐Eibrink, M. M., Sonneveld, P., & Pieters, R. (2000) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp38094 · Cited by 124
Kast, C., & Gros, P. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.42.26479 · Cited by 112
A Role for P-Glycoprotein in Regulating Cell Death
Johnstone, R. W., Ruefli, A. A., Tainton, K. M., & Smyth, M. J. (2000) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190009060314 · Cited by 109
Duesberg, P., Stindl, R., & Hehlmann, R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.201398998 · Cited by 106
Gene rearrangement: a novel mechanism for MDR-1 gene activation.
Mickley, L. A., Spengler, B. A., Knutsen, T. A., Biedler, J. L., & Fojo, T. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119362 · Cited by 96
Aromatase Inhibitors for Breast Cancer in Postmenopausal Women
Campos, S. M. (2004) · The Oncologist · doi:10.1634/theoncologist.9-2-126 · Cited by 95
Biological rationale for endocrine therapy in breast cancer
Miller, W. R. (2003) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/s1521-690x(03)00044-7 · Cited by 93
Naruse, I., Ohmori, T., Ao, Y., Fukumoto, H., Kuroki, T., Mori, M., Saijo, N., & Nishio, K. (2001) · International Journal of Cancer · doi:10.1002/ijc.10173 · Cited by 89
Dunn, T. A., Schmoll, H., Grünwald, V., Bokemeyer, V., & Casper, J. (1997) · Investigational New Drugs · doi:10.1023/a:1005800520747 · Cited by 88
Burger, H., Nooter, K., Boersma, A. W. M., van Wingerden, K. E., Looijenga, L. H. J., Jochemsen, A. G., & Stoter, G. (1999) · International Journal of Cancer · Cited by 87
Active Efflux of CPT-11 and Its Metabolites in Human KB-Derived Cell Lines
Chu, X., Suzuki, H., Ueda, K., Kato, Y., Akiyama, S., & Sugiyama, Y. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38014-0 · Cited by 86
Immunomodulatory effects of tumor-associated fibroblasts in colorectal-tumor development
Lieubeau, B., Heymann, M., Henry, F., Barbieux, I., Méflah, K., & Gr�goire, M. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990517)81:4<629::aid-ijc20>3.0.co;2-8 · Cited by 86
Ruefli, A. A., Smyth, M. J., & Johnstone, R. W. (2000) · Blood · doi:10.1182/blood.v95.7.2378 · Cited by 84
Gene therapy to protect haematopoietic cells from cytotoxic cancer drugs
Sorrentino, B. P. (2002) · Nature reviews. Cancer · doi:10.1038/nrc823 · Cited by 82
Pearson, J., Fogler, W. E., Völker, K., Usui, N., Goldenberg, S. K., Gruys, E., Riggs, C. W., Komschlies, K. L., Wiltrout, R. H., TSURUO, T., et al. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.19.1386 · Cited by 82
Molecular predictors of response to chemotherapy in lung cancer
Rosell, R., Tarón, M., Ariza, A., et al. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.12.011 · Cited by 81
Ruefli, A. A., Tainton, K. M., Darcy, P. K., Smyth, M. J., & Johnstone, R. W. (2002) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401081 · Cited by 76
Targeting the HER-kinase axis in cancer
Gross, M. E., Shazer, R. L., & Agus, D. B. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.01.005 · Cited by 74
Kast, C., & Gros, P. (1998) · Biochemistry · doi:10.1021/bi972332v · Cited by 70
Meyers, M. B., Merluzzi, V. J., Spengler, B. A., & Biedler, J. L. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.15.5521 · Cited by 64
The folate receptor as a potential therapeutic anticancer target
Gruner, B. A., & Weitman, S. D. (1998) · Investigational New Drugs · doi:10.1023/a:1006147932159 · Cited by 61
Sclabas, G. M., Fujioka, S., Schmidt, C., Fan, Z., Evans, D. B., & Chiao, P. J. (2003) · Journal of Gastrointestinal Surgery · doi:10.1016/s1091-255x(02)00088-4 · Cited by 56
Multidrug resistance mechanisms in chronic lymphocytic leukaemia
Consoli, U., Santonocito, A., Stagno, F., Fiumara, P. F., Privitera, A., Parisi, G. C., Giustolisi, G. M., Pavone, B., Palumbo, G. A., Raimondo, F. D., et al. (2002) · British Journal of Haematology · doi:10.1046/j.0007-1048.2002.03344.x · Cited by 44
Monoclonal antibody therapy for breast cancer: Herceptin
Finn, R. S., & Slamon, D. J. (2003) · Cancer chemotherapy and biological response modifiers · doi:10.1016/s0921-4410(03)21010-3 · Cited by 39
Pawlak, W., Żołnierek, J., Sarosiek, T., & Szczylik, C. A. (2000) · Cancer Treatment Reviews · doi:10.1053/ctrv.2000.0173 · Cited by 35
Increased rate of glutathione synthesis from cystine in drug-resistant MCF-7 cells
Gamcsik, M. P., Dubay, G. R., & Cox, B. R. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00931-5 · Cited by 30
Selivanova, G. (2001) · PubMed · Cited by 27
Meyers, M. B., Yu, P., & Mendelsohn, J. M. (1993) · Biochemical Pharmacology · doi:10.1016/0006-2952(93)90591-j · Cited by 16
Cited by
Mechanisms of Multidrug Resistance in Cancer Chemotherapy
Bukowski, K., Kciuk, M., & Kontek, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093233 · Cited by 1,757
Angiogenic signaling pathways and anti-angiogenic therapy for cancer
Liu, Z.-L., Chen, H.-H., Zheng, L.-L., Sun, L.-P., & Shi, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01460-1 · Cited by 1,300
Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment
Phi, L. T. H., Sari, I. N., Yang, Y.-G., Lee, S.-H., Jun, N., Kim, K. S., Lee, Y. K., & Kwon, H. Y. (2018) · Stem Cells International · doi:10.1155/2018/5416923 · Cited by 994
ABC Transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development
Choi, Y., & Yu, A.-M. (2014) · Current Pharmaceutical Design · doi:10.2174/138161282005140214165212 · Cited by 629
Recent advances in stealth coating of nanoparticle drug delivery systems
Amoozgar, Z., & Yeo, Y. (2012) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1157 · Cited by 528
Metadata
- Authors
- Luqmani, Y. A.
- Venue
- Medical Principles and Practice
- Publisher
- S. Karger AG
- Published
- 2005
- Volume
- 14
- Issue
- Suppl. 1
- Pages
- 35-48
- ISSN
- 1011-7571 (ISSN-L)
- 1423-0151
- OpenAlex
- W2035253718
- Cited by
- 651
- References
- 105
- FWCI
- 4.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.